Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03570749 · OUTCOME

Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata · Source last updated 2026-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Week 52

What was measured

ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.

Analysis population: All randomized phase 3 open-label addendum participants with baseline ClinRO measure for EL hair loss ≥ 2 and who had evaluable data for this outcome measure.

Groups in this outcome

4 mg Baricitinib Phase 3 Open-Label Addendum

Participants who received one 4 mg Baricitinib tablet administered orally QD.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
4 mg Baricitinib Phase 3 Open-Label Addendum3

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
4 mg Baricitinib Phase 3 Open-Label Addendum66.7Not reported20.893.9Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        20.8
        upper Limit
        93.9
        value
        66.7
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    units
    Participants
description
ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants who received one 4 mg Baricitinib tablet administered orally QD.
    id
    OG000
    title
    4 mg Baricitinib Phase 3 Open-Label Addendum
param Type
NUMBER
population Description
All randomized phase 3 open-label addendum participants with baseline ClinRO measure for EL hair loss ≥ 2 and who had evaluable data for this outcome measure.
reporting Status
POSTED
time Frame
Week 52
title
Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice